ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
Vertex Pharma’s vision for reimbursement innovationAs regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s Share XVertex Pharma’s vision for reimbursement innovationhttps://pharmaphorum.com/views-analysis-market-access/vertex-pharmas-vision-for-reimbursement-innovation/
Moderna broadens R&D scope with Vertex, Chiesi alliancesAll eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle Share XModerna broadens R&D scope with Vertex, Chiesi allianceshttps://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis tripleNHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after Share XCelebrations as NHS England agrees deal for Vertex’ cystic fibrosis triplehttps://pharmaphorum.com/news/celebrations-as-nhs-england-agrees-deal-for-vertex-cystic-fibrosis-triple/
As CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealCystic fibrosis patient groups in the UK are celebrating a recommendation by the EMA’s human medicines committee to Share XAs CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealhttps://pharmaphorum.com/news/as-chmp-backs-vertex-cf-triple-campaigners-plead-for-speedy-uk-deal/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
Vertex gets early okay for cystic fibrosis triple Trikafta in USVertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a Share XVertex gets early okay for cystic fibrosis triple Trikafta in UShttps://pharmaphorum.com/news/vertex-gets-early-okay-for-cystic-fibrosis-triple-trikafta-in-us/
Labour government would use compulsory licensing for expensive drugsA Labour government would force pharma companies to make essential drugs available that are affordable by the NHS, Share XLabour government would use compulsory licensing for expensive drugshttps://pharmaphorum.com/news/labour-government-would-use-compulsory-licensing-for-expensive-drugs/
